Govt Caps Cancer Drug Margins to Save Patients ₹2,500 Crore
The government has capped margins on non-scheduled anti-cancer drugs at 30% of MRP, potentially reducing prices by 70% and saving patients ₹2,500 crore annually.
In a major move to ease the financial burden on patients, the Indian government has approved a new price cap on the margins charged for the supply and sale of non-scheduled anti-cancer drugs. This strategic intervention is expected to slash medicine prices by as much as 70%, providing a massive relief of ₹2,500 crore annually to cancer patients across the country.
Targeting Excessive Mark-ups in the Supply Chain
While essential cancer medicines already included in the scheduled list are subject to strict ceiling prices, many other life-saving drugs fall under the "non-scheduled" category. Currently, these non-scheduled medicines are subject to significant price hikes as they move through the supply chain. An analysis by the National Pharmaceutical Pricing Authority (NPPA) revealed that non-scheduled anti-cancer medicines carry an average price mark-up of approximately 170%, with some cases seeing increases of 700% or more.
The new regulation will limit these margins to 30% of the Maximum Retail Price (MRP). This decision aims to curb excessive profiteering and address unfair pricing practices that have long plagued the pharmaceutical market. Previously, patients faced varying costs depending on whether they purchased medication from a retail pharmacy, a hospital pharmacy, or an online platform.
Rising Cancer Incidence and Financial Strain
The necessity of this move comes at a critical time for India’s healthcare landscape. Cancer incidence is on the rise, with approximately 60 people per lakh population being affected. The cost of treatment often imposes a devastating financial burden on families, who are frequently forced to pay substantial amounts out of their own pockets.
Concerns regarding these excessive prices have been raised by various state authorities, including those in Maharashtra, Rajasthan, and Karnataka, as well as by civil society groups. The gap between the procurement price for retailers and the final MRP charged to consumers has been a primary point of contention.
A Proven Strategy for Patient Relief
This latest intervention builds upon the success of a similar government action taken in February 2019. At that time, the NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs under the Drugs (Prices Control) Order, 2013. That single move reduced MRPs by up to 91%, resulting in reported annual savings of ₹984 crore across 526 different brands.
By expanding this cap, the government aims to ensure fairer pricing for a wider range of medicines. The new rules will cover various categories of non-scheduled anti-cancer drugs, including:
- Branded and generic medicines
- Domestically produced and imported drugs
- Patented and non-patented medicines
Ensuring Medicine Availability
While the primary goal is price reduction, the government has also taken steps to ensure that these life-saving drugs remain readily available in the market. To prevent supply shortages, manufacturers of non-scheduled anti-cancer drugs will be required to maintain their current production levels.
The implementation process will involve an expert committee under the Directorate General of Health Services (DGHS) to finalize the specific list of medicines to be covered. Once finalized, the NPPA will issue the official notification to enact the new pricing structure.